🇺🇸 SECNOVO NORDISK A SQwen · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 18:00:11待核·⟳ 抓取 18:04:05·⚡ 决策 09-09 20:50:33 +2h46m·48.1 天前
诺和诺德6-K披露股份回购计划例行进展：截至9月4日累计回购3203万股B股、耗资约90.2亿丹麦克朗，无新增规模或条款变化
读完6-K全文后确认这是按MAR安全港规则强制提交的周度回购进展备案：所有关键参数（150亿丹麦克朗总上限、2月4日起12个月执行期、5月6日子计划DKK 112亿上限）均为既有已公开信息，本次仅新增五天的成交明细和累计进度。跨源已处理消息库在72小时窗口内未召回同催化记录（该工具未命中不等于首发），但即便如此，回购进度更新对盈利、现金流、指引或竞争格局没有新增方向性信息，回购本身是已宣布的资本返还承诺的常规执行；库存股仅占1.0%，剩余约60亿丹麦克朗额度分散在5个月内执行，日均约21万股（相对日成交量属边际买盘）。因此不存在可交易的edge，价格、行情、先例或产业链映射都不会改变“不做”的结论，直接早停输出AVOID。
📄 原文NOVO NORDISK A S↗ 原文
----- f6k_090726.htm ----- 6-K 1 f6k_090726.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D…
不做 诺和诺德（NVO.US）
例行周度回购进展备案，无增量事实：150亿丹麦克朗总上限、2月4日起12个月执行期与5月6日子计划上限均为既有公开信息，本次仅新增5天成交明细与累计进度（已用约60%额度、库存股占1.0%），未上调/下调授权、未终止、未附任何业绩或监管新信息，方向与edge均不存在；此外抓取时点美股处于盘前不可成交、A股港股已收盘，也无执行窗口
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事实：诺和诺德9月7日提交6-K，内容为8月31日至9月4日B股回购明细（合计105.5万股、约3.14亿丹麦克朗）及累计进度（自2月4日累计3203万股、90.22亿丹麦克朗，占总上限150亿的约60%），库存股占总股本1.0%。影响链：回购计划在2月4日和5月6日已完整公开规模与期限，本次披露只是执行进度报告，未改变股本结构预期、未上调/下调授权、未终止，也未附带任何业绩、产品或监管新信息；对每股盈利的摊薄/增厚效应在计划宣布时已被定价。证据：全文逐行核对未见金额或条款变化；跨源已处理消息库72小时检索0命中，但这只说明近期没有同源重复记录，不改变事件性质。结论：属于例行行政性备案，无增量事实、无方向、无可交易edge，对NVO.US与哥本哈根B股均不做，也不产生风险信号。
🔎 新鲜度:最早出现 2026-09-07 · 扩散 low · price-in 风险 high ↗
反向证据
- 做多前查反向 · 来源 filing · 日期 2026-09-07 · 影响 none
正文仅含五个交易日的成交明细、子计划与总计划累计进度、库存股占比1.0%及公司简介，未出现任何授权变更、指引或经营新信息；回购价格区间291.92-305.35丹麦克朗也未显示执行节奏异常加速
检索:6-K正文核对：是否上调回购授权、宣布新计划、终止计划或附带业绩/产品/监管新信息 原文 ↗
先例如何影响了这次决策
对本次决策的影响:对最终决策无影响；在早停判定“无增量事实”后未启动先例检索，避免为无催化事件消耗研究预算
方向:无可用先例；且本事件为例行进度备案，先例统计不改变结论
涨幅量级:未做幅度校准：回购上限与期限均为既有公开信息，本次无新增幅度可测
形态:无见光死/高开低走判断，因为不存在需要定价的新催化
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 81 ms
{"result": "search_processed_events:agent query=`dkk 15 billion share repurchase 4 february 2026 | novo nordisk 6-k treasury shares | novo nordisk b shares buyback transactions weekly update | novo nordisk share repurchase progra`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 28.7/72 小时、1535 条本臂决策(完整)，返回 0 条候选。未命中只表示这些
原文全文
展开原文 · 4,170 字
----- f6k_090726.htm -----
6-K
1
f6k_090726.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
September 7, 2026
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F ☒
Form 40-F ☐
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 07 September 2026 –
On 6 May 2026, Novo Nordisk initiated
a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April
2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part
of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period
from 6 May 2026 to 1 February 2027.
Since the announcement 31 August, the following transactions have been made:
Number
of
B
shares
Average
purchase
price
Transaction
value, DKK
Accumulated, last announcement
16,220,000
4,907,673,815
31 August 2026
210,000
291.92
61,302,771
1 September 2026
215,000
293.94
63,196,785
2 September 2026
215,000
297.42
63,945,131
3 September 2026
215,000
305.35
65,649,697
4 September 2026
200,000
300.03
60,006,094
Accumulated under the programme
17,275,000
5,221,774,293
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated
above, Novo Nordisk owns a total of 46,074,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.0% of the share capital. The
total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As
of 4 September 2026, Novo Nordisk has since 4 February 2026 repurchased a total 32,034,179 B shares at an average share price of DKK 281.63
per B share equal to a transaction value of DKK 9,021,774,283.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark.
Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific
breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800
people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn
and YouTube.
Contacts for further information
Media:
Ambre James-Brown
Liz Skrbkova (US)
+45 3079 9289
+1 609 917 0632
globalmedia@novonordisk.com
USMediaRelations@novonordisk.com
Investors:
Michael Novod
Sina Meyer
+45 3075 6050
+45 3079 6656
nvno@novonordisk.com
azey@novonordisk.com
Alex Bruce
Ida Schaap Melvold
+45 3444 2613
+45 3077 5649
axeu@novonordisk.com
idmg@novonordisk.com
Christoffer Togo Solgaard-Tullin
Mads Berner Bruun
+45 3079 1471
+45 3075 2936
cftu@novonordisk.com
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com
Novo Nordisk A/S
Investor Relations
Novo Allé 1
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
www.novonordisk.com
CVR no: 24 25 67 90
Company
announcement No 54 / 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: September 7, 2026
NOVO NORDISK A/S
Maziar Mike Doustdar
Chief Executive Officer
6-K
1
f6k_090726.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
September 7, 2026
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F ☒
Form 40-F ☐
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 07 September 2026 –
On 6 May 2026, Novo Nordisk initiated
a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April
2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part
of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period
from 6 May 2026 to 1 February 2027.
Since the announcement 31 August, the following transactions have been made:
Number
of
B
shares
Average
purchase
price
Transaction
value, DKK
Accumulated, last announcement
16,220,000
4,907,673,815
31 August 2026
210,000
291.92
61,302,771
1 September 2026
215,000
293.94
63,196,785
2 September 2026
215,000
297.42
63,945,131
3 September 2026
215,000
305.35
65,649,697
4 September 2026
200,000
300.03
60,006,094
Accumulated under the programme
17,275,000
5,221,774,293
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated
above, Novo Nordisk owns a total of 46,074,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.0% of the share capital. The
total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As
of 4 September 2026, Novo Nordisk has since 4 February 2026 repurchased a total 32,034,179 B shares at an average share price of DKK 281.63
per B share equal to a transaction value of DKK 9,021,774,283.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark.
Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific
breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800
people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn
and YouTube.
Contacts for further information
Media:
Ambre James-Brown
Liz Skrbkova (US)
+45 3079 9289
+1 609 917 0632
globalmedia@novonordisk.com
USMediaRelations@novonordisk.com
Investors:
Michael Novod
Sina Meyer
+45 3075 6050
+45 3079 6656
nvno@novonordisk.com
azey@novonordisk.com
Alex Bruce
Ida Schaap Melvold
+45 3444 2613
+45 3077 5649
axeu@novonordisk.com
idmg@novonordisk.com
Christoffer Togo Solgaard-Tullin
Mads Berner Bruun
+45 3079 1471
+45 3075 2936
cftu@novonordisk.com
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com
Novo Nordisk A/S
Investor Relations
Novo Allé 1
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
www.novonordisk.com
CVR no: 24 25 67 90
Company
announcement No 54 / 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: September 7, 2026
NOVO NORDISK A/S
Maziar Mike Doustdar
Chief Executive Officer
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。